Search company, investor...

GEMoaB

gemoab.com

Founded Year

2011

About GEMoaB

GEMoaB is a privately-owned, clinical-stage biopharmaceutical company that is aiming to become a fully integrated biopharmaceutical company. By advancing its proprietary UniCAR, RevCAR and ATAC platforms, the company will discover, develop, manufacture and commercialize immunotherapies for the treatment of cancer patients with a high unmet medical need.

Headquarters Location

Tatzberg 47

Dresden, 01307,

Germany

+49 351 4466 4500

Missing: GEMoaB's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: GEMoaB's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

GEMoaB Patents

GEMoaB has filed 12 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/8/2018

1/24/2023

Clusters of differentiation, Immune system, Immunology, Autoimmune diseases, Monoclonal antibodies

Grant

Application Date

6/8/2018

Grant Date

1/24/2023

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Autoimmune diseases, Monoclonal antibodies

Status

Grant

Latest GEMoaB News

Trastuzumab deruxtecan shows ‘terrific activity’ in second line for breast cancer subset

Mar 23, 2022

Disclosures: Cortés reports consultant/advisory roles with, honoraria from, research funding to his institution from, stocks, patents and intellectual property with, and/or travel, accommodations and expenses from Ariad Pharmaceuticals, AstraZeneca, Athenex, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Bioasis Technologies, BioInvent, Boehringer Ingelheim, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Eisai, Ellipses, Erytech, F. Hoffmann-La Roche, HiberCell, GEMoaB, Gilead, GlaxoSmithKline, Guardant Health, Leuko, Lilly, Medica Scientia Innovation Research, Menarini, Merck Sharp & Dohme, Nektar Therapeutics, Novartis, Pfizer, Piqur Therapeutics, Polyphor, Puma Biotechnology, Queen Mary University of London, Reveal Genomics, Roche, Samsung Bioepis, Seagen and Zymeworks. Please see the study for all other authors’ relevant disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Results of the multicenter, open-label, randomized phase 3 DESTINY-Breast03 trial, published in The New England Journal of Medicine, also showed an association of trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) with adjudicated interstitial lung disease and pneumonitis, although researchers reported numerically lower incidence than in previous trials. Data derived from Cortés S, et al. N Engl J Med. 2022;doi:10.1056/NEJMoa2115022. “The activity we observed with trastuzumab deruxtecan in the late-line setting was so great that we wanted to explore it in earlier lines,” Javier Cortés, MD, PhD, director of International Breast Cancer Center in Barcelona, Spain, told Healio. “Trastuzumab deruxtecan should replace trastuzumab emtansine as the preferred option in the second-line setting.” Background and methodology Javier Cortés Cortés and colleagues pursued the research to compare the efficacy and safety of trastuzumab deruxtecan, a HER2 antibody-drug conjugate, against trastuzumab emtansine — also known as ado-trastuzumab emtansine (Kadcyla, Genentech) and T-DM1 — the current standard of care for patients with HER2-positive metastatic breast cancer whose disease has progressed after treatment with a combination of anti-HER2 antibodies and a taxane. The analysis included 524 patients randomly assigned to trastuzumab deruxtecan (n = 261; median age, 54.3 years; 58.2% Asian; 27.2% white) or trastuzumab emtansine (n = 263; median age, 54.2 years; 61.6% Asian; 27.4% white). PFS as determined by blinded independent central review served as the primary endpoint; secondary endpoints included OS, objective response and safety. Key findings At 12 months, 75.8% (95% CI, 69.8-80.7) of patients who received trastuzumab deruxtecan remained alive without disease progression vs. 34.1% (95% CI, 27.7 to 40.5) of those who received trastuzumab emtansine (HR for progression or death due to any cause = 0.28; 95% CI, 0.22-0.37). Moreover, 94.1% (95% CI, 90.3-96.4) of patients in the trastuzumab deruxtecan group remained alive at 12 months vs. 85.9% (95% CI, 80.9-89.7) of the trastuzumab emtansine group (HR for death = 0.55; 95% CI, 0.36-0.86; prespecified significance boundary not reached). More than twice as many patients who received trastuzumab deruxtecan had an overall (complete or partial) response (79.7%; 95% CI, 74.3-84.4) vs. those who received trastuzumab emtansine (34.2%; 95% CI, 28.5-40.3), including a higher percentage with a complete response (16.1% vs. 8.7%). Cortés told Healio he was surprised by what he deemed “the impressive HR of PFS and the great number of patients with a complete response.” In toxicity analysis, researchers reported drug-related adverse events of any grade among 98.1% of the trastuzumab deruxtecan group (45.1% grade 3 or grade 4) and 86.6% of the trastuzumab emtansine group (39.8% grade 3 or grade 4). They noted 10.5% of patients in the trastuzumab deruxtecan group experienced adjudicated drug-related interstitial lung disease or pneumonitis vs. 1.9% in the trastuzumab emtansine group — none grade 4 or grade 5. Implications Cortés said trastuzumab deruxtecan exhibited “terrific activity” in patients with HER2-positive metastatic breast cancer previously treated with taxanes and trastuzumab. “Although the interstitial lung disease and pneumonitis were less frequent and severe compared with trastuzumab emtansine, we should carefully follow our patients and treat this event as soon as possible if it happens,” Cortés said. “We also should not forget that the great majority of patients with HER2-positive metastatic breast cancer still die as a consequence of this disease, so more treatment options are clearly needed.” He said further research should focus on strategies to decrease interstitial lung disease and pneumonitis, obtain more data in patients with brain metastases and explore trastuzumab deruxtecan’s activity in the early breast cancer setting. For more information: Javier Cortés, MD, PhD, can be reached at International Breast Cancer Center, Marquesa de Vilallonga 12, 08017, Barcelona, Spain; email: jacortes@vhio.net. Read more about

GEMoaB Frequently Asked Questions (FAQ)

  • When was GEMoaB founded?

    GEMoaB was founded in 2011.

  • Where is GEMoaB's headquarters?

    GEMoaB's headquarters is located at Tatzberg 47, Dresden.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.